Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pretax income is the income that a company earns before paying income taxes. Integra Lifesciences Holdings's pretax income for the
three
months ended in Jun. 2026 was $5 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Jun. 2026 was $-0 Mil.
Integra Lifesciences Holdings's pretax margin was 1.13%.
During the past 13 years, Integra Lifesciences Holdings's highest Pretax Margin was 13.92%. The lowest was -34.46%. And the median was 4.61%.
During the past 13 years, Integra Lifesciences Holdings's highest Pretax Margin was 13.92%. The lowest was -34.46%. And the median was 4.61%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integra Lifesciences Holdings Pre-Tax Income Related Terms
Integra Lifesciences Holdings Pre-Tax Income Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integra Lifesciences Holdings Pre-Tax Income Chart
IART vs ENOV, AHCO, INSP: Pre-Tax Income Comparison
For the Medical Devices subindustry, Integra Lifesciences Holdings's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integra Lifesciences Holdings Pre-Tax Income vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Integra Lifesciences Holdings's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Integra Lifesciences Holdings's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integra Lifesciences Holdings (IART) has a Pre-Tax Income of $-0 Mil as of Jun. 2026. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Integra Lifesciences Holdings and its competitors.
Is Integra Lifesciences Holdings' Pre-Tax Income too high?
Integra Lifesciences Holdings' current Pre-Tax Income is $-0 Mil. Overall, Integra Lifesciences Holdings has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Integra Lifesciences Holdings' Pre-Tax Income compare to ENOV and AHCO?
Integra Lifesciences Holdings' Pre-Tax Income of $-0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pre-Tax Income for a Medical Devices & Instruments company?
A good Pre-Tax Income depends on the Medical Devices & Instruments industry context. However, Pre-Tax Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pre-Tax Income mean?
A high Pre-Tax Income can signal that a stock is expensive relative to its fundamentals. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Integra Lifesciences Holdings and its competitors. Integra Lifesciences Holdings's current Pre-Tax Income is $-0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integra Lifesciences Holdings stock overvalued right now?
Based on GuruFocus' analysis, Integra Lifesciences Holdings (IART) is currently considered Modestly Undervalued. The stock's GF Value™ is $20.52, compared to a current price of $16.69 — trading 18.7% below its estimated fair value. The current Pre-Tax Income is $-0 Mil. Integra Lifesciences Holdings' overall GF Score™ is 70/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pre-Tax Income calculated?
Pre-Tax Income is calculated from a company's financial statements. For Integra Lifesciences Holdings (IART), the current Pre-Tax Income is $-0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integra Lifesciences Holdings (IART) Overvalued in 2026?
Based on GuruFocus' analysis, Integra Lifesciences Holdings stock appears to be undervalued.
The current stock price of $16.69 is trading 18.7% below its estimated GF Value™ of $20.52.
GuruFocus considers Integra Lifesciences Holdings to be Modestly Undervalued.
Key valuation signals for IART:
Pre-Tax Income: $-0 Mil
GF Value™: $20.52 vs. price of $16.69 (18.7% below fair value)
No single metric tells the full story. See the IART stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.
70GF Score
Get the complete analysis for IART
Pre-Tax Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IART has been successfully added to your 
